Publicaciones en colaboración con investigadores/as de Hospital Universitario Pío del Río Hortega (14)

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Dolutegravir Plus 3TC in Virologically Suppressed PLWHIV: Immunological Outcomes in a Multicenter Retrospective Cohort in Spain during the COVID-19 Pandemic

    Viruses, Vol. 15, Núm. 2

2022

  1. A bacteraemia risk prediction model: development and validation in an emergency medicine population

    Infection, Vol. 50, Núm. 1, pp. 203-221

  2. Clinical Features and Risk Factors for Mortality Among Long-term Care Facility Residents Hospitalized Due to COVID-19 in Spain

    Journals of Gerontology - Series A Biological Sciences and Medical Sciences, Vol. 77, Núm. 4, pp. E138-E147

  3. Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study

    Medicine (United States), Vol. 101, Núm. 24, pp. E29252

2021

  1. Demographic, clinical, and functional determinants of antithrombotic treatment in patients with nonvalvular atrial fibrillation

    BMC Cardiovascular Disorders, Vol. 21, Núm. 1

2020

  1. Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. Diverse large HIV-1 non-subtype B clusters are spreading among men who have sex with men in Spain

    Frontiers in Microbiology, Vol. 10, Núm. APR

2018

  1. Analysis of the scientific production of the Spanish Society of Paediatric Emergencies (SEUP) in the period 2011-2017

    Anales de Pediatria

2017

  1. New insights into the genetic component of non-infectious uveitis through an Immunochip strategy

    Journal of Medical Genetics, Vol. 54, Núm. 1, pp. 38-46

2015

  1. Specific association of IL17A genetic variants with panuveitis

    British Journal of Ophthalmology, Vol. 99, Núm. 4, pp. 566-570

  2. Study of association of CTLA4 gene variants to non-anterior uveitis

    Tissue Antigens, Vol. 86, Núm. 5, pp. 373-376

2008

  1. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of hiv type 1 infection: Final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903

    Clinical Infectious Diseases, Vol. 47, Núm. 8, pp. 1083-1092

  2. Low rate of adverse hepatic events associated with fosamprenavir/ritonavir-based antiretroviral regimens

    HIV Clinical Trials, Vol. 9, Núm. 5, pp. 309-313